Early switch from run-in with targeted to immunotherapy in advanced BRAF-positive melanoma: final results of the randomised phase II ImmunoCobiVem trialE. Livingstone, Dirk Schadendorf, Dimitrios C. Ziogas et al.|ESMO Open|2025Cited by 4
LBA45 Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trialD. Schadendorf, E. Livingstone, H. Gogas et al.|Annals of Oncology|2024Cited by 3
1168P Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examinedJ-M. Placke, S. Ugurel-Becker, Martin Kimmig et al.|Annals of Oncology|2023Cited by 1
Prognostic factors and outcomes in metastatic uveal melanoma treated with PD-1 or combined PD-1 / CTLA-4 inhibitionMarkus V. Heppt, Carola Berking, Lucie Heinzerling et al.|Journal Der Deutschen Dermatologischen Gesellschaft|2017Cited by 0
Genetic characterization and clinical outcome of melanoma of unknown primary (MUP) with comparison to melanoma with known primary (MKP)Georg Lodde, E. Livingstone, J. Dollani et al.|EJC Skin Cancer|2025Cited by 0